$15,829.79 speaking Payment -- Eli Lilly and Company to Dr. Amanda Lewis

Neurologist Receives Over $15,000 for Speaking Engagement on Xarelto from Eli Lilly

This page provides a detailed analysis of a $15,829.79 speaking payment from Eli Lilly and Company to Dr. Amanda Lewis. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$15,829.79
Payment Typespeaking
Payment NatureCompensation for serving as faculty or as a speaker
Pharmaceutical CompanyEli Lilly and Company
PhysicianDr. Amanda Lewis
NPI Number1801712333
Physician SpecialtyNeurology
LocationCity, CO
Date of Payment2024-12-27
Related Drug/DeviceXarelto
Conflict AssessmentModerate -- Worth Noting

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Eli Lilly and Company made a $15.8K speaking payment to Amanda Lewis, a Neurology specialist in City, CO. The payment was associated with Xarelto. The payment of $15,829.79 to Dr. Amanda Lewis from Eli Lilly and Company is for speaking engagements. This payment is associated with Xarelto, a drug commonly prescribed for anticoagulation. The payment was made on December 27, 2024, indicating a recent engagement.

Patient Guidance: What This Payment Means for You

If your doctor receives payments for speaking about medications, it's important to discuss how this might influence their recommendations and ensure you understand all treatment options. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Payments for speaking engagements can vary widely, but this amount for a neurology-related topic is on the higher end compared to some other specialties.

Regulatory Context: Sunshine Act Requirements

Physicians must disclose payments received from pharmaceutical companies, and these payments are publicly available through the CMS Open Payments program.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding speaking Payments

Speaking and education payments compensate physicians for presenting at conferences, continuing medical education (CME) events, and promotional speaking engagements. These payments often cover honoraria, preparation time, and travel expenses. Speaking fees are among the highest-value payment categories and have attracted significant attention from researchers studying potential conflicts of interest.

Frequently Asked Questions About This Payment

What was this $15.8K payment for?

This was a speaking payment of $15.8K from Eli Lilly and Company to Amanda Lewis, categorized as "Compensation for serving as faculty or as a speaker". It was associated with Xarelto. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Amanda Lewis accept pharmaceutical money?

Yes, Amanda Lewis received this $15.8K payment from Eli Lilly and Company. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Amanda Lewis's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this speaking payment?

A speaking payment of $15.8K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Neurology?

To compare this payment against Neurology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Neurology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Amanda Lewis's relationship with Eli Lilly and Company?

The payment amount is substantial for a single speaking engagement. This $15.8K speaking payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Neurology?

The nature of the payment is explicitly for serving as faculty or speaker.

What should patients do after learning about this payment?

If your doctor receives payments for speaking about medications, it's important to discuss how this might influence their recommendations and ensure you understand all treatment options.

What else should I know about this speaking payment?

The drug Xarelto is a key focus of this payment.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.